{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:25:20Z","timestamp":1788283520729,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007342","name":"Willis-Ekbom Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.mayocp.2013.06.016","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T01:06:15Z","timestamp":1377911175000},"page":"977-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Willis-Ekbom Disease Foundation Revised Consensus Statement on the Management of Restless Legs Syndrome"],"prefix":"10.1016","volume":"88","author":[{"given":"Michael H.","family":"Silber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Garcia-Borreguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2013.06.016_bib1","series-title":"International Classification of Sleep Disorders: Diagnostic and Coding Manual","year":"2005"},{"issue":"9","key":"10.1016\/j.mayocp.2013.06.016_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.sleep.2008.09.015","article-title":"The four diagnostic criteria for restless legs syndrome are unable to exclude confounding conditions (\u201cmimics\u201d)","volume":"10","author":"Hening","year":"2009","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.mayocp.2013.06.016_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.23430","article-title":"Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States","volume":"26","author":"Allen","year":"2011","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2013.06.016_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.sleep.2009.03.007","article-title":"Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics","volume":"11","author":"Allen","year":"2010","journal-title":"Sleep Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.06.016_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.sleep.2010.07.007","article-title":"Restless legs syndrome: understanding its consequences and the need for better treatment","volume":"11","author":"Earley","year":"2010","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.06.016_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/sleep\/23.5.1b","article-title":"Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients","volume":"23","author":"Winkelmann","year":"2000","journal-title":"Sleep"},{"issue":"8","key":"10.1016\/j.mayocp.2013.06.016_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.sleep.2011.06.006","article-title":"Association studies of variants in MEIS1, BTBD9, and MAP2K5\/SKOR1 with restless legs syndrome in a US population","volume":"12","author":"Yang","year":"2011","journal-title":"Sleep Med"},{"issue":"pt 4","key":"10.1016\/j.mayocp.2013.06.016_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/brain\/awr012","article-title":"Profile of altered brain iron acquisition in restless legs syndrome","volume":"134","author":"Connor","year":"2011","journal-title":"Brain"},{"issue":"pt 9","key":"10.1016\/j.mayocp.2013.06.016_bib9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/brain\/awp125","article-title":"Altered dopaminergic profile in the putamen and substantia nigra in restless legs syndrome","volume":"132","author":"Connor","year":"2009","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.mayocp.2013.06.016_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4065\/79.7.916","article-title":"An algorithm for the mangement of restless legs syndrome","volume":"79","author":"Silber","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mayocp.2013.06.016_bib11","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","article-title":"Long-term use of pramipexole in the mangement of restless legs syndrome","volume":"13","author":"Lipford","year":"2012","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.06.016_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A\u00a010-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.mayocp.2013.06.016_bib13","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.mayocp.2013.06.016_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","article-title":"Efficacy of rotigotine for tretament of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Trenkwalder","year":"2008","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2013.06.016_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(11)70127-2","article-title":"Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study","volume":"10","author":"Oertel","year":"2011","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.06.016_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e318259eac8","article-title":"A\u00a0randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome","volume":"35","author":"Lal","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"10.1016\/j.mayocp.2013.06.016_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.sleep.2011.06.009","article-title":"Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"issue":"2","key":"10.1016\/j.mayocp.2013.06.016_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.sleep.2007.12.006","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome","volume":"10","author":"Earley","year":"2009","journal-title":"Sleep Med"},{"issue":"10","key":"10.1016\/j.mayocp.2013.06.016_bib19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/mds.22562","article-title":"A\u00a0randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome","volume":"24","author":"Grote","year":"2009","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.mayocp.2013.06.016_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/sleep\/27.3.560","article-title":"An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine review","volume":"27","author":"Hening","year":"2004","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.mayocp.2013.06.016_bib21","first-page":"970","article-title":"The treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine Review","volume":"22","author":"Hening","year":"1999","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.mayocp.2013.06.016_bib22","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","article-title":"European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society","volume":"19","author":"Garcia-Borreguero","year":"2012","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.mayocp.2013.06.016_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5665\/sleep.1986","article-title":"The treatment of restless legs syndrome and periodic limb movement disorder in adults: an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline","volume":"35","author":"Aurora","year":"2012","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.mayocp.2013.06.016_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless legs Syndrome Study Group","volume":"14","author":"Garc\u00eda-Borreguero","year":"2013","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.mayocp.2013.06.016_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ageing\/23.3.200","article-title":"Iron status and restless legs syndrome in the elderly","volume":"23","author":"O'Keeffe","year":"1994","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.mayocp.2013.06.016_bib26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/21.4.381","article-title":"Iron and the restless legs syndrome","volume":"21","author":"Sun","year":"1998","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.mayocp.2013.06.016_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.sleep.2008.11.003","article-title":"Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study","volume":"10","author":"Wang","year":"2009","journal-title":"Sleep Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.06.016_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.sleep.2008.12.003","article-title":"The importance of oral iron therapy in restless legs syndrome","volume":"10","author":"Earley","year":"2009","journal-title":"Sleep Med"},{"issue":"4","key":"10.1016\/j.mayocp.2013.06.016_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3122\/jabfm.2011.04.100173","article-title":"Bupropion and restless legs syndrome: a randomized controlled trial","volume":"24","author":"Bayard","year":"2011","journal-title":"J\u00a0Am Board Fam Med"},{"issue":"10","key":"10.1016\/j.mayocp.2013.06.016_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/sleep\/19.10.801","article-title":"Pergolide and carbidopa\/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients","volume":"19","author":"Earley","year":"1996","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.mayocp.2013.06.016_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.43.2.445","article-title":"Dopaminergic treatment of restless legs and rebound phenomenon","volume":"43","author":"Guilleminault","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2013.06.016_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1017\/S1461145712000922","article-title":"Effects of pregabalin on sleep in generalized anxiety disorder","volume":"16","author":"Holsboer-Trachsler","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.06.016_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14656566.2013.758251","article-title":"Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1-3 mg\/24 h for up to 5 years","volume":"14","author":"Dohin","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.mayocp.2013.06.016_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","article-title":"Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute","volume":"8","author":"Garc\u00eda-Borreguero","year":"2007","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.06.016_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/sj.ki.5002779","article-title":"Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease","volume":"73","author":"Auerbach","year":"2008","journal-title":"Kidney Int"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613005594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613005594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:28:54Z","timestamp":1758418134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613005594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0025619613005594"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2013.06.016","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Willis-Ekbom Disease Foundation Revised Consensus Statement on the Management of Restless Legs Syndrome","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2013.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}